Moberg Pharma AB (publ) operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Moberg Pharma AB (publ) with three other
pharmaceutical manufacturers in Europe:
sales of 31.81 million Euro [US$37.11 million]
Horizon Discovery Group PLC
of the United Kingdom
(£36.51 million [US$47.98 million]
of which 62%
was Products), and
Venture Life Group plc
based in the United Kingdom
(£16.05 million [US$21.09 million]
Moberg Pharma AB (publ) reported sales of SEK 439.03 million (US$49.49 million)
December of 2017.
increase of 31.3%
versus 2016, when the company's sales were SEK 334.30 million.
Sales at Moberg Pharma AB (publ) have increased during each of the previous five years
(and since 2012, sales have increased a total of 290%).
Sales of Divested Products (Jointflex , Fergon , saw an increase
that was more than double the company's growth rate: sales were up
115.2% in 2017, from
SEK 16.32 million to SEK 35.12 million.
Not all segments of Moberg Pharma AB (publ) experienced an increase in sales in 2017:
sales of Other Products fell 19.8% to SEK 65.85 million.